comparison between Intralesional injection of 2% zinc sulfate and intralesional glucantime in treatment of cutaneous leishmaniasis.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000115235

Enrollment

Registered

2009-02-18

Start date

2009-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Leishmaniasis is a parasitic disease that is endemic in developing countries such as our country. The incidence of leishmaniasis is more than 400,000 cases annually and the prevalence of all form of leishmaniasis is more than twelve millions. Although cutaneous leishmaniasis (CL) is a self- healing disease , the duration of the disease is long and requeries several months and somtimes years before complete recovery , depending on the species of the infecting parasite . After recovery, a disfiguring scar can be left , which may destroy underlying structures like the nose or ear or cause psychological suffering of patients. The first line drug for treatment of CL., according to WHO recommendation , is the pentavalent comounds such as meglomine antimoniate (Glucantime ) Other treatment for cutaneous leishmaniasis are intralesinal injection of meglomine antimonate, terbinafine , paramonycin ointment , and physical treatment including cryotherapy (cryosurgery) .In recent researches,zinc sulfate was studied in the treatment of this disease.But there are some contravesies.The aim of this study is the comparision of intralesional injection of zinc sulfate with intralesional glucantim in the treatment of cutaneou leishmaniasis.

Interventions

intraleisional injection of zinc sulfate 2% vial once every week until 10 weeks or until complete healing if happened earliear plus crotherapy at -196 degree celsius (liqiud nitrogen) once every other week until 10 weeks or until complete healing if happened earliear; it is performed as contact cryotherapy for 5-10 sec to the infected site

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

5 Years to 60 Years

Healthy volunteers

Inclusion criteria

the patients with urban cutaneous leishmaniasis with the onset of lower than 3 months

Exclusion criteria

taking any treatment of leishmaniasis within last month

Outcome results